XML 28 R5.htm IDEA: XBRL DOCUMENT v3.25.1
Consolidated Statements of Comprehensive Loss - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Income Statement [Abstract]      
Revenues $ 522 $ 82 $ 45
Cost of revenues (437) (62) (10)
GROSS PROFIT 85 20 35
Research and development, net (Note 7. a) (2,964) (3,316) (2,271)
Sales and marketing expenses, net (2,096) (2,008) (1,370)
General and administrative expenses (2,845) (2,882) (1,948)
Initial public offering expenses (904)
OPERATING LOSS (7,820) (8,186) (6,458)
Financing income (expenses), net (52) 372 (38)
LOSS BEFORE TAX EXPENSES (7,872) (7,814) (6,496)
Tax expenses (7)
NET LOSS AND TOTAL COMPREHENSIVE LOSS $ (7,879) $ (7,814) $ (6,496)
Net loss per ordinary shares, basic (in Dollars per share) [1] $ (24.2) $ (38.4) $ (42.4)
Net loss per ordinary shares, diluted (in Dollars per share) [1] $ (24.2) $ (38.4) $ (42.4)
Weighted average number of ordinary shares and pre-funded warrants outstanding basic (in Shares) [1] 325,690 202,515 153,465
Weighted average number of ordinary shares and pre-funded warrants outstanding diluted (in Shares) [1] 325,690 202,515 153,465
[1] The share and per share information in these financial statements reflects the 1-for-20 reverse share split that became effective on October 10, 2024 and an additional 1-for-4 reverse share split of the Company’s issued and outstanding ordinary shares that became effective on March 17, 2025 (the “Reverse Share Splits”). See also Note 1c.